Headache & Migraine Disease Working Group
Headache & Migraine Disease Working Group The Headache and Migraine Disease Working Group is a network of policy-minded health care providers who advocate for patient-centered care. By participating in advocacy initiatives and the development of educational resources, working group members ensure that the clinician’s perspective informs policy discussions that impact health care for people living […]
Diabetes Therapy Access Working Group
Diabetes Therapy Access Working Group The Diabetes Therapy Access Working Group is a network of policy-minded health care providers who advocate for patient-centered care. By participating in advocacy initiatives and the development of educational resources, working group members ensure that the clinician’s perspective informs policy discussions that impact health care for people living with diabetes. […]
Cardiovascular Disease Working Group
Cardiovascular Disease Working Group The Cardiovascular Disease Working Group is a network of policy-minded health care providers who advocate for patient-centered care. By participating in advocacy initiatives and the development of educational resources, working group members ensure that the clinician’s perspective informs policy discussions that impact cardiovascular health. To learn more, or to join AfPA’s […]
Biologic Therapy Access Working Group
Biologic Therapy Access Working Group The Biologic Therapy Access Working Group is a network of policy-minded health care providers who advocate for patient-centered care. By participating in advocacy initiatives and the development of educational resources, working group members ensure that the clinician’s perspective informs policy discussions on biologics and biosimilars. To learn more, or to […]
ICER Asthma Report
ICER Alzheimer’s Report
Who decides which medications are available to the 5 million Americans living with Alzheimer’s? Increasingly, questions of access are informed by the Institute for Clinical and Economic Review, or ICER. The health economics organization uses clinical trials data and available pricing information to consider whether a drug is worth its cost. Now, ICER is reviewing […]
Drug Pricing Proposals Raise Access Questions
A handful of new executive orders from President Donald Trump could have serious implications for patient access.
You’re Invited
Managing Cognitive and Behavioral Symptoms in Parkinson’s Disease for Advanced Practice Providers Managing Cognitive and Behavioral Symptoms in Parkinson’s Disease is a two-day, non-accredited educational course for advanced practice providers hosted by the non-profit Institute for Patient Access. The course will address practice gaps in the treatment of Parkinson’s disease patients who suffer from cognitive […]
ICER Videos
If you don’t know ICER, you should. IfPA’s new videos explain what the health economic organization is leaving out of its analysis – and why it matters. What’s Wrong With ICER? Sometimes economists can have more control than your doctor about whether you get the medicine that treats your condition. Why Health Care Providers Should […]
Let ICER Hear From You
A health economics organization called the Institute for Clinical and Economic Review is publishing a migraine report that soon could influence whether your patients can access the medicine you prescribe. Your input is vital. What is ICER? ICER, or the Institute for Clinical and Economic Review, is a non-governmental health economics organization that analyzes drugs’ […]
